CONMED (CNMD): Capital Research holds 1,032,733 shares, 3.3% stake
Capital Research Global Investors filed Amendment No. 3 to Schedule 13G on CONMED Corp. (CNMD), reporting beneficial ownership of 1,032,733 shares of common stock, representing 3.3% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Capital Research Global Investors filed Amendment No. 3 to Schedule 13G on CONMED Corp. (CNMD), reporting beneficial ownership of 1,032,733 shares of common stock, representing 3.3% of the class.
The filer reports sole voting power over 1,032,733 shares and sole dispositive power over 1,032,733 shares, with no shared power. The filing identifies the reporting person type as IA (investment adviser). The ownership is certified as acquired and held in the ordinary course and not for the purpose of changing or influencing control.
CRGI notes its 3.3% is based on 30,954,963 shares believed to be outstanding. The date of event requiring the filing is 09/30/2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Capital Research report in the CNMD Schedule 13G/A?
What voting and dispositive powers were disclosed for CNMD (CNMD)?
What is the basis for the 3.3% ownership in CNMD?
What type of filer is Capital Research in this 13G/A?
When was the event date that triggered this CNMD filing?
Does the filing indicate an intent to influence control of CONMED?
AI-generated analysis. How Rhea-AI works. Not financial advice.